Peregrine Pharmaceuticals (PPHM) Shares are Up 5.01%

Peregrine Pharmaceuticals (PPHM) : Traders are bullish on Peregrine Pharmaceuticals (PPHM) as it has outperformed the S&P 500 by a wide margin of 15.22% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.83%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 5.01% in the last 1 week, and is up 14.61% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 7.82% and the 50-Day Moving Average is 13.18%.The 200 Day SMA reached 22.33%


Peregrine Pharmaceuticals (NASDAQ:PPHM): After opening at $0.43, the stock dipped to an intraday low of $0.415 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $0.4399 and the buying power remained strong till the end. The stock closed at $0.43 for the day, a gain of 0.84% for the day session. The total traded volume was 1,152,553. The stocks close on the previous trading day was $0.43.

Peregrine Pharmaceuticals (PPHM) : The most positive equity analysts on Peregrine Pharmaceuticals (PPHM) expects the shares to touch $2, whereas, the least positive believes that the stock will trade at $1 in the short term. The company is covered by 3 Wall Street Brokerage Firms. The average price target for shares are $1 with an expected fluctuation of $0.5 from the mean.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for the treatment and diagnosis of cancer. The Company has two platforms and is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab, its phosphatidylserine (PS) targeting agent, PGN65, and its brain cancer therapy Cotara. Bavituximab is the Companys therapeutic PS-targeting antibody. PGN650 is its PS-targeting imaging agent. The Company is evaluating the bavituximab investigator-sponsored trials (IST) in front-line, HER2-negative metastatic breast cancer, liver cancer, rectal adenocarcinoma and advanced melanoma. It is also evaluating PGN650 imaging in multiple solid tumor types. The Company`s Impavido biomanufacturing subsidiary Avid Bioservices, Inc., provides commercial and clinical manufacturing services for the Company and third-party clients.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.